196 related articles for article (PubMed ID: 7989945)
1. Fluorouracil, doxorubicin, and mitomycin combination versus PELF chemotherapy in advanced gastric cancer: a prospective randomized trial of the Italian Oncology Group for Clinical Research.
Cocconi G; Bella M; Zironi S; Algeri R; Di Costanzo F; De Lisi V; Luppi G; Mazzocchi B; Rodinò C; Soldani M
J Clin Oncol; 1994 Dec; 12(12):2687-93. PubMed ID: 7989945
[TBL] [Abstract][Full Text] [Related]
2. The combination of cisplatin, doxorubicin, and mitomycin (PAM) compared with the FAM regimen in treating advanced gastric carcinoma. A phase II randomized trial of the Italian Oncology Group for Clinical Research.
De Lisi V; Cocconi G; Angelini F; Cavicchi F; Di Costanzo F; Gilli G; Rodinò C; Soldani M; Tonato M; Finardi C
Cancer; 1996 Jan; 77(2):245-50. PubMed ID: 8625230
[TBL] [Abstract][Full Text] [Related]
3. Cisplatin, epirubicin, leucovorin and 5-fluorouracil (PELF) is more active than 5-fluorouracil, doxorubicin and methotrexate (FAMTX) in advanced gastric carcinoma.
Cocconi G; Carlini P; Gamboni A; Gasperoni S; Rodinò C; Zironi S; Bisagni G; Porrozzi S; Cognetti F; Di Costanzo F; Canaletti R; Ruggeri EM; Camisa R; Pucci F;
Ann Oncol; 2003 Aug; 14(8):1258-63. PubMed ID: 12881389
[TBL] [Abstract][Full Text] [Related]
4. 5-Fluorouracil, epirubicin, and mitomycin C versus 5-fluorouracil, epirubicin, mitomycin C, and leucovorin in advanced gastric carcinoma. A randomized trial.
Tsavaris NB; Tentas K; Kosmidis P; Mylonakis N; Sakelaropoulos N; Kosmas C; Lisaios B; Soumilas A; Mandrekois D; Tsetis A; Klonaris C
Am J Clin Oncol; 1996 Oct; 19(5):517-21. PubMed ID: 8823483
[TBL] [Abstract][Full Text] [Related]
5. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer.
Kim NK; Park YS; Heo DS; Suh C; Kim SY; Park KC; Kang YK; Shin DB; Kim HT; Kim HJ
Cancer; 1993 Jun; 71(12):3813-8. PubMed ID: 8508349
[TBL] [Abstract][Full Text] [Related]
6. [Evaluation of the efficacy and toxicity of protocol cisplatin, 5-fluorouracil, leucovorin compared to protocol fluorouracil, doxorubicin and mitomycin C in locally advanced and metastatic gastric cancer].
Andrić Z; Randjelović T; Kovčin V; Gutović J; Crevar S; Murtezani Z; Kostić S
Srp Arh Celok Lek; 2012; 140(5-6):305-12. PubMed ID: 22826983
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancer.
Cascinu S; Graziano F; Barni S; Labianca R; Comella G; Casaretti R; Frontini L; Catalano V; Baldelli AM; Catalano G
Br J Cancer; 2001 Feb; 84(4):470-4. PubMed ID: 11207039
[TBL] [Abstract][Full Text] [Related]
8. Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.
Vanhoefer U; Rougier P; Wilke H; Ducreux MP; Lacave AJ; Van Cutsem E; Planker M; Santos JG; Piedbois P; Paillot B; Bodenstein H; Schmoll HJ; Bleiberg H; Nordlinger B; Couvreur ML; Baron B; Wils JA
J Clin Oncol; 2000 Jul; 18(14):2648-57. PubMed ID: 10894863
[TBL] [Abstract][Full Text] [Related]
9. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
Webb A; Cunningham D; Scarffe JH; Harper P; Norman A; Joffe JK; Hughes M; Mansi J; Findlay M; Hill A; Oates J; Nicolson M; Hickish T; O'Brien M; Iveson T; Watson M; Underhill C; Wardley A; Meehan M
J Clin Oncol; 1997 Jan; 15(1):261-7. PubMed ID: 8996151
[TBL] [Abstract][Full Text] [Related]
10. Bi-weekly chemotherapy with cisplatin, epirubicin, folinic acid and 5-fluororacil continuous infusion plus g-csf in advanced gastric cancer: a multicentric phase II study.
Felici A; Carlini P; Ruggeri EM; Gamucci T; Pollera CF; De Marco S; Fariello AM; Moscetti L; Gelibter A; Adami E; Sperduti I; Cognetti F
Cancer Chemother Pharmacol; 2006 Jan; 57(1):59-64. PubMed ID: 16001173
[TBL] [Abstract][Full Text] [Related]
11. Retrospective comparison of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (modified FAM) combination chemotherapy versus palliative therapy in treatment of advanced gastric cancer.
Park JO; Chung HC; Cho JY; Rha SY; You NC; Kim JH; Noh SH; Kim CB; Min JS; Kim BS; Roh JK
Am J Clin Oncol; 1997 Oct; 20(5):484-9. PubMed ID: 9345333
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of epirubicin, cisplatin, oral uracil and tegafur, and leucovorin in patients with advanced gastric carcinoma.
Jeen YT; Yoon SY; Shin SW; Kim BS; Mok YJ; Kim CS; Hyun JH; Kim JS; Kim YH
Cancer; 2001 Jun; 91(12):2288-93. PubMed ID: 11413517
[TBL] [Abstract][Full Text] [Related]
13. New developments in the treatment of gastric carcinoma.
Wilke H; Preusser P; Fink U; Achterrath W; Meyer HJ; Stahl M; Lenaz L; Meyer J; Siewert JR; Geerlings H
Semin Oncol; 1990 Feb; 17(1 Suppl 2):61-70. PubMed ID: 2305269
[TBL] [Abstract][Full Text] [Related]
14. Chemotherapy for hormonally refractory advanced prostate carcinoma. A comparison of combined versus sequential treatment with mitomycin C, doxorubicin, and 5-fluorouracil.
Laurie JA; Hahn RG; Therneau TM; Patel SR; Mailliard JA; Windschitl HE; Twito DI; Morton RF; Krook JE
Cancer; 1992 Mar; 69(6):1440-4. PubMed ID: 1540881
[TBL] [Abstract][Full Text] [Related]
15. Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) in locally advanced or metastatic gastric cancer: a single institution experience.
Aitini E; Rabbi C; Mambrini A; Cavazzini G; Pari F; Zamagni D; Cantore M; Pagani M; Sorio M; Lusenti A; Adami F; Smerieri F
Tumori; 2001; 87(1):20-4. PubMed ID: 11669552
[TBL] [Abstract][Full Text] [Related]
16. A phase II trial of 5-fluorouracil, doxorubicin, mitomycin C, and leucovorin in advanced gastric carcinoma.
Arbuck SG; Silk Y; Douglass HO; Nava H; Rustum YM; Milliron S
Cancer; 1990 Jun; 65(11):2442-5. PubMed ID: 2337858
[TBL] [Abstract][Full Text] [Related]
17. A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5-fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma. Turkish Oncology Group.
Içli F; Celik I; Aykan F; Uner A; Demirkazik A; Ozet A; Ozgüroğlu M; Taş F; Akbulut H; Firat D
Cancer; 1998 Dec; 83(12):2475-80. PubMed ID: 9874451
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy in gastric cancer: an economic evaluation of the FAM (5-fluorouracil, adriamycin, mitomycin C) versus ELF (etoposide, leucovorin, 5-fluorouracil) regimens.
Norum J; Angelsen V
J Chemother; 1995 Oct; 7(5):455-9. PubMed ID: 8596132
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin, mitomycin-C, 5-fluorouracil and leucovorin combination chemotherapy (l-FCM) in locally advanced unresectable or metastatic gastric carcinoma: a phase-II study.
Bobbio-Pallavicini E; Tacconi F; Porta C; Brambilla G; Mainardi E; Bianchessi C; Moroni M
Oncol Rep; 2001; 8(1):167-71. PubMed ID: 11115592
[TBL] [Abstract][Full Text] [Related]
20. OK-432 and 5-fluorouracil, doxorubicin, and mitomycin C (FAM-P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma: a randomized Phase III trial.
Kim SY; Park HC; Yoon C; Yoon HJ; Choi YM; Cho KS
Cancer; 1998 Nov; 83(10):2054-9. PubMed ID: 9827708
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
